Azitra, Inc.

AMEX:AZTR

Biotechnology

Healthcare
$1.53 +113.99%

+$0.82 today

Market cap
$92.72M
Beta
-1.04
P/E (TTM)
-1.2
EPS (TTM)
-$0.64
52W Low $0.05High $2.13

Volume 146.25M

Average 11.12M

AZTR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Azitra, Inc.AMEX: AZTR

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of $1.35M fell 3.6% year over year, behind the +6.5% change in trailing-twelve-month research & development. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at -7.4% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -3.6% toward the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.35M-13.4% QoQ
Last fiscal yearDec 2025
$4.84M+2.4% YoY
LTMJun 2026
$5.1M+6.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.6%——
1 year+2.4%——
3-year CAGR-7.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
4.84M USD
Year-over-year change
+2.4%
4-year CAGR
-2.6%

Research & Development vs competitors

How AZTR compares with its peers on the latest reported figures

  • AZTR's LTM Jun 2026 research & development of $5.1M is the lowest of the 2 companies compared; the peer median is $7.02M.
  • Its year-over-year change of +6.5% is the highest of 2, against a peer median of -17.1%.
  • Over three fiscal years its annual growth of -7.4% compares with a peer median of +13.9%.
AZTR Competitors Peer median
Research & Development for AZTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$7.02M -17.1%+13.9%—
AZTRAzitra, Inc.LTM Jun 2026$5.1M +6.5%-7.4%—
Peer median (excluding AZTR) $7.02M-17.1%+13.9%—

Competitors are the stored peer set for AZTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110K284K686K7.5K0
Cost of Revenue00000
Gross Profit110K284K686K7.5K0
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development5.38M6.1M3.64M4.72M4.84M
Selling, General & Admin3.95M3.64M4.49M6.27M6.13M
Operating Expenses9.33M9.74M8.14M10.99M10.97M
Depreciation & Amortization84.77K405.98K425.55K448.24K453.14K
EBITDA(8.79M)(10.02M)(10.67M)(8.5M)(10.49M)
EBITDA Margin-7989.0%-3529.0%-1555.9%-113307.5%—
Operating Income(9.22M)(9.45M)(7.45M)(10.99M)(10.97M)
Operating Margin-8383.1%-3328.7%-1086.1%-146468.5%—
Interest Income8.76K4.82K1.58K122.55K70.21K
Interest Expense66.97K251.89K167.73K12.16K7.59K
Other Income / Expenses281.78K(1.23M)(3.82M)2.03M19.61K
Income Before Tax(8.94M)(10.68M)(11.27M)(8.96M)(10.95M)
Pre-Tax Margin-8127.0%-3760.7%-1642.3%-119446.1%—
Income Tax Expense0017.31K9.03K8.32K
Net Income(8.94M)(10.68M)(11.28M)(8.97M)(10.96M)
Net Margin-8127.0%-3760.7%-1644.9%-119566.6%—
EPS (Basic)(193.55)(222.33)(208.74)(15.78)(2.25)
EPS (Diluted)(193.55)(222.33)(208.74)(15.78)(2.25)
Weighted Avg Shares60.49K60.49K60.55K568.24K4.87M
Weighted Avg Shares (Diluted)60.49K60.49K60.55K568.24K4.87M

Azitra, Inc.

AMEX:AZTR

Intrinsic Alpha fair value

Locked

Current Price

$1.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.